KALA KALA BIO, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $3.89M | $11.24M |
| R&D expense | $18.78M | $22.09M | $18.59M | $17.65M | $11.52M |
| SG&A expense | $23.63M | $18.34M | $20.57M | $65.03M | $105.06M |
| Operating income | -$39.16M | -$40.98M | -$39.66M | -$81.71M | -$130.25M |
| Interest expense | $3.28M | $5.78M | $5.81M | $7.27M | $8.38M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.98M | -$38.51M | -$42.20M | -$44.82M | -$142.60M |
| EBITDA | -$38.84M | -$40.72M | -$39.36M | -$81.17M | -$129.27M |
| EPS (basic) | -3.31 | -10.15 | -17.35 | -29.48 | -108.32 |
| EPS (diluted) | -3.31 | -10.15 | -17.35 | -29.48 | -108.32 |
| Weighted avg. shares (diluted) | 8.15M | 3.80M | 2.43M | 1.52M | 1.32M |
| Balance sheet | |||||
| Cash & equivalents | $7.56M | $51.18M | $50.90M | $70.50M | $92.14M |
| Receivables | — | — | — | $195,000 | $15.35M |
| Inventory | — | — | — | — | $8.64M |
| Current assets | $9.49M | $52.80M | $52.87M | $85.94M | $124.37M |
| PP&E, net | — | $749,000 | $753,000 | $400,000 | $2.72M |
| Total assets | $9.49M | $55.48M | $55.95M | $86.82M | $139.43M |
| Current liabilities | $2.49M | $16.96M | $8.35M | $25.68M | $37.42M |
| Short-term debt | — | $10.34M | — | $5.00M | — |
| Long-term debt | — | $20.10M | $34.19M | $37.94M | $78.93M |
| Total debt | — | $30.44M | $34.19M | $42.94M | $78.93M |
| Total liabilities | $2.49M | $43.15M | $48.45M | $67.85M | $122.62M |
| Shareholders' equity | $7.00M | $12.33M | $7.50M | $18.97M | $16.80M |
| Net debt | — | -$20.74M | -$16.70M | -$27.56M | -$13.21M |
| Shares outstanding | 556,995 | 6.09M | 2.76M | 1.71M | 1.32M |
| Cash flow statement | |||||
| Operating cash flow | -$31.99M | -$29.38M | -$27.93M | -$78.91M | -$108.23M |
| Investing cash flow | -$15,000 | -$208,000 | -$429,000 | $62.72M | $70.80M |
| Financing cash flow | -$11.62M | $29.88M | $8.51M | -$7.94M | $42.55M |
| Depreciation & amortization | $317,000 | $259,000 | $303,000 | $537,000 | $975,000 |
| Stock-based compensation | $7.00M | $8.39M | $7.46M | $7.01M | $16.09M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.